CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial

Table 5 Summary of the detection of ADA and NAb in the enrolled patients

Case number	The time of collection (Blood sample, weeks)	ADA	NAb
29	30	+	+
69	30	+	–
102	6	+	+
120	12	+	–
139	0	+^a	+
139	12	+	–
193	6	+	+
234	6	+	+
242	12	+	–
438	0	+^a	–
467	0	+^a	+
510	0	+^a	+

ADA, anti-drug antibodies; NAb, neutralizing antibodies
^aPre-existing ADA: ADA present in samples from treatment-naïve subjects or ADA in pre-dose (CMAB009) subject samples

ISSN: 2523-3548

Case number	The time of collection (Blood sample, weeks)	ADA	NAb
29	30	+	+
69	30	+	–
102	6	+	+
120	12	+	–
139	0	+^a	+
139	12	+	–
193	6	+	+
234	6	+	+
242	12	+	–
438	0	+^a	–
467	0	+^a	+
510	0	+^a	+

Case number	The time of collection (Blood sample, weeks)	ADA	NAb
29	30	+	+
69	30	+	–
102	6	+	+
120	12	+	–
139	0	+^a	+
139	12	+	–
193	6	+	+
234	6	+	+
242	12	+	–
438	0	+^a	–
467	0	+^a	+
510	0	+^a	+

Case number	The time of collection (Blood sample, weeks)	ADA	NAb
29	30	+	+
69	30	+	–
102	6	+	+
120	12	+	–
139	0	+^a	+
139	12	+	–
193	6	+	+
234	6	+	+
242	12	+	–
438	0	+^a	–
467	0	+^a	+
510	0	+^a	+